No Data
No Data
No Data
No Data
No Data
Bankrupt PhaseBio Pharma Finds Buyers for Secondary Assets After Auction -- Market Talk
1601 ET - Publicly traded PhaseBio Pharmaceuticals, which has already reached a deal to sell its key drug program during its bankruptcy, says it has also found proposed buyers for its secondary assets
Dow JonesJan 24, 2023 05:04
SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets From PhaseBio Pharmaceuticals
SFJ Pharmaceuticals ("SFJ" or the "company") today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. ("PhaseBio") to SFJ. The sale and transfer was
BusinesswireJan 17, 2023 23:46
Delisting of Securities of PhaseBio Pharmaceuticals, Inc.; Zovio Inc.; Fast Radius, Inc.; and Kismet Acquisition Three Corp. From The Nasdaq Stock Market
NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of PhaseBio Pharmaceuticals, Inc. PhaseBio Pharmaceuticals, Inc.'s common stock was suspended on
GlobeNewswireDec 21, 2022 05:05
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Trading Up 7%
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) shares were up 7% during trading on Wednesday . The stock traded as high as $0.11 and last traded at $0.10. Approximately 455,938 shares chan
Financial News LiveNov 17, 2022 13:42
Bankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assets
By Becky Yerak Chiesi Farmaceutici SpA has been named as the lead bidder for the key assets of PhaseBio Pharmaceuticals Inc., a publicly traded drug developer that is in chapter 11 bankruptcy. Phase
Dow JonesNov 8, 2022 00:21
Head-To-Head Contrast: Alpine Immune Sciences (NASDAQ:ALPN) Vs. PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) and PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the
Defense WorldNov 2, 2022 13:31
No Data
No Data